Skip to main content

Advertisement

Log in

Role of complement and antibodies in the control and facilitation of HIV disease

  • Special report
  • Published:
Pathology & Oncology Research

Abstract

In humans the HIV infection results in a chronic disease with a permanent fight between factors controlling HIV and the escape of the virus. Fromthese control mechanisms the present review summarizes the role betwen complement and autoantibodies; the competition of complement and anti-HIV antibodies for binding sites, the role of mannan-binding lectin in the susceptibility to and in the survival after HIV infection, the contribution of complement-dependent enhancing type antibodies to the clinical progression of HIV disease as well as the changing pattern of some autoantibodies (mimicking MHC class II molecules, anti-heat shock protein 60 antibodies and anti-C1q antibodies) which were found to correlate to immunological and clinical parameters.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Banapour B, Sernatinger J, and Levy JA: The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum. Virology 152:268–271, 1986.

    Article  PubMed  CAS  Google Scholar 

  2. Bartholomew RM, Esser AF, and Müller-Eberhard HJ: Lysis of oncornaviruses by human serum. J Exp Med 147:844–853, 1978.

    Article  PubMed  CAS  Google Scholar 

  3. Bartz SR, Pauza CD, Ivanyi J, et al: An Hsp60 related protein is associated with purified HIV and SIV. J Med Primatol 23:151–154, 1994.

    PubMed  CAS  Google Scholar 

  4. Denner J, Norley S, and Kurth R: The immunosuppressive pep- tide of HIV-1: functional domains and immune response in AIDS patients. AIDS 8:1063–1072, 1994.

    Article  PubMed  CAS  Google Scholar 

  5. Ebenhichler CF, Thielens NM, Vornhagen R, et al: Human immunodeficiency virus type-1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 174:1417–1424, 1991.

    Article  Google Scholar 

  6. El Jarrah F, Hidvégi T, Ujhelyi E, et al: Complement activation decreases the ability of HIV transmembrane envelope protein to bind to specific antibody. AIDS 6:1050–1051, 1992.

    Article  PubMed  CAS  Google Scholar 

  7. Elsaghier A, Pranter C, Bothamley G, et al: Disease association of antibodies to human and mycobacterial hsp70 and hsp60 stress proteins. Clin Exp Immunol 89: 305–309, 1992.

    PubMed  CAS  Google Scholar 

  8. Ezekowitz RA, Kuhlman M, Groopman JE, and Byrn RA: A human serum mannose-binding protein inhibits in vitro infection by human immunodeficiency virus. J Exp Med 169:185- 196, 1989.

    Article  PubMed  CAS  Google Scholar 

  9. Frank I, Stoiber H, Godar S, et al: Acquisition of host cell-sur-face-derived molecules by HIV-1. AIDS 10: 1611–1620, 1996.

    PubMed  CAS  Google Scholar 

  10. Füst G, Ujhelyi E, Hidvégi T, et al: The complement system in HIV disease. Immunol Invest 20: 231–241, 1991.

    Article  PubMed  Google Scholar 

  11. Füst G, Prohászka Z, Hidvégi T, et al: Competition of comple- ment proteins and specific antibodies for binding to HIV-1 envelope antigens. Acta Microbiol Immunol Hung 41:Suppl. 27–31, 1994.

    PubMed  Google Scholar 

  12. Füst G, Tóth DF, Kiss J, et al: Neutralizing and enhancing anti- bodies measured in complement-restored serum samples from HIV-1 infected individuals correlate with immunosuppression and disease. AIDS 8: 603–609, 1994.

    PubMed  Google Scholar 

  13. Füst G: Enhancing antibodies in HIV-1 infection. Parasitology (in press) 1997.

  14. Garred P, Madsen HO, Hoffmann B, and Svejgard A: Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. The Lancet 349:236–240, 1997.

    Article  CAS  Google Scholar 

  15. Gnann Jr.JW, Nelson JA, and Oldstone BA: Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol 61:2639–2641, 1987.

    PubMed  CAS  Google Scholar 

  16. Haurum JS, Thiel S, Jones IM, et al: Complement activation upon binding of mannan-binding protein to HIV envelope gly-coproteins. AIDS 7:1307–1313, 1993.

    Article  PubMed  CAS  Google Scholar 

  17. Hidvégi T, Prohászka Z, Ujhelyi E, et al: Studies on the mecha- nism of complement-mediated inhibition of antibody binding to gp41. Clin Exp Immunol 94:490–493, 1993.

    PubMed  Google Scholar 

  18. Holmskov U, Malhotra R, Sim RB, and Jensenius JC: Collectins: collagenous C-type lectins of the innate immune defense system. Immunology Today 15:67–73, 1994.

    Article  PubMed  CAS  Google Scholar 

  19. Hoshino H, Tanaka H, Miwa M, and Okada H: Human T-cell leukemia virus is not lysed by human serum. Nature 310:324- 325, 1984.

    Article  PubMed  CAS  Google Scholar 

  20. June RA, Schade SZ, Bankowski MJ, et al: Complement and antibody mediate enhancement of HIV infeciton by increasing virus binding and provirus formation. AIDS 5:269–274, 1991.

    Article  PubMed  CAS  Google Scholar 

  21. Kieber-Emmons T, Jameson BA, and Morrow WJW: The gp120- CD4 interface: structural, immunological and pathological considerations. Biochem Biophys Acta 989:281, 1989.

    PubMed  CAS  Google Scholar 

  22. Lund O, Hansen J, Sorensen AM, et al: Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection. J Virol 69:2393–2400, 1995.

    PubMed  CAS  Google Scholar 

  23. Montefiori DC, Robinson, WE, Jr,Hirsch, VM, et al: Antibodydependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. J Virol 64:113–119, 1990.

    PubMed  CAS  Google Scholar 

  24. Montefiori DC, Lefkowitz LB, Keller RE, et al: Absence of clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1 infected individuals. AIDS 5:513–517, 1991.

    Article  PubMed  CAS  Google Scholar 

  25. Montefiori DC, Pantaleo G, Fink LM, et al: Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term non-progressors. J Infect Dis 173:60–67, 1996.

    PubMed  CAS  Google Scholar 

  26. Nielsen SL, Andersen PL, Koch C, et al: The level of serum opsonin, mannan-binding protein in HIV-1 antibody positive patients. Clin Exp Immunol 100:219–222, 1995.

    PubMed  CAS  Google Scholar 

  27. Perelson AS, Neumann AU, Markovitz M, et al: HIV-1 dinamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582–1586, 1996.

    Article  PubMed  CAS  Google Scholar 

  28. Prohászka Z, Hidvégi T, Ujhelyi E, et al: Interaction of comple- ment and specific antibodies with the extenal glycoprotein 120 of HIV-1. Immunology 85:184–189, 1995.

    PubMed  Google Scholar 

  29. Prohászka Z, Bánhegyi D, Ujhelyi E, et al: Antibodies against 60kD heat shock proteins in human immunodeficiency virus infeciton.. Ann NY Acad Sci, 1997. (accepted for publication)

  30. Prohászka Z, Nemes J, Hidvégi T, et al: Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection. AIDS 11:949–958, 1997.

    Article  PubMed  Google Scholar 

  31. Prohászka Z, Thiel S, Ujhelyi E, et al: Mannan-binding lectin (MBL) serum concentrations in HIV infected patients are influenced by the stage of disease. Immunol Lett 58:171–175, 1997.

    Article  PubMed  Google Scholar 

  32. Ratner L, Haseltine W, Patarca R, et al: Complete nucleotide sequence of the AIDS-virus, HTLV-III. Nature 313:277, 1985.

    Article  PubMed  CAS  Google Scholar 

  33. Robinson WE, Jr,Montefiori DC, Gillespie DH, and Michell WM: Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA synthesis and infectious virus release. J AIDS 2:33- 42, 1989.

    CAS  Google Scholar 

  34. Robinson WE, Jr,Montefiori DC, Mitchell WM, et al: Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1 infected and passively immunized chimpanzees. Proc Natl Acad Sci USA 86:4710–4714, 1989.

    Article  PubMed  Google Scholar 

  35. Senaldi G, Davies ET, Mahalingam M. et al: Circulating levels of mannose binding protein in human imunodeficiency virus infection. J Infect 31:145–148, 1995.

    Article  PubMed  CAS  Google Scholar 

  36. Sölder BM, Schulz TE, Hengster P, et al: HIV and HIV infected cells differentially activate the human complement system independent of antibody. Immunol Lett 22:135–146, 1989.

    Article  PubMed  Google Scholar 

  37. Spear GT, Takefman DM, Sullivan BL, et al: Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol 67:53–59, 1993.

    PubMed  CAS  Google Scholar 

  38. Stoiber H, Clivio A, and Dierich MP: Role of complement in HIV infection. Ann Rev Immunol 15:649–674, 1997.

    Article  CAS  Google Scholar 

  39. Stoiber H, Thielens NM, Ebenbichler C, et al: The envelope glycoprotein gp120 of HIV-1 and human complement protein C1q bind to the same peptides derived from three different regions of gp41, the transmembrane glycoprotein of HIV-1, and share antigenic homology. Eur J Immunol 24:294–300, 1994.

    Article  PubMed  CAS  Google Scholar 

  40. Süsal C, Daniel V, and Opelz G: Does AIDS emerge from a dis- equilibrium between two complementary groups of moleculaes that mimic the MHC? Immunology Today 17:114–119, 1996.

    Article  PubMed  Google Scholar 

  41. Süsal C, Kirschfink M, Kröpelin M, et al: Complement activa- tion by recombinant HIV-1 glycoprotein gp120. J Immunol 152:6028–6034, 1994

    PubMed  Google Scholar 

  42. Thiel S: Mannan-binding protein, a complement activating animal lectin. Immunopharmacology 24:91–99, 1992.

    Article  PubMed  CAS  Google Scholar 

  43. Thielens NM, Bally IM, Ebenbichler CF, et al: Further charac- terization of the interaction between the C1q subcomponent of human C1 and the transmembrane envelope glycoprotein gp41 of HIV-1. J Immunol 151:6583–6592, 1993.

    PubMed  CAS  Google Scholar 

  44. Tóth DF, Bánhegyi D, Szabó J, et al: Complement-mediated antibody-dependent enhancement of HIV infection correlates to viral load and predicts progression of HIV disease.(submitted to AIDS, 1997).

  45. Tóth DF, Süsal C, Ujhelyi E, et al: Comparative study of autoan- tibodies that are associated with disease progression in HIV disease. Immunol Lett 41:33–36, 1994.

    Article  PubMed  Google Scholar 

  46. Tóth DF, Szabó B, Ujhelyi E, et al: Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection. AIDS 5:263–268, 1991.

    Article  PubMed  Google Scholar 

  47. Turner MW: Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunology Today 17:532–540, 1996.

    Article  PubMed  CAS  Google Scholar 

  48. Welsh RM, Cooper NR, Jensen FC, and Oldstone MBA: Human serum lyses RNA tumor viruses. Nature 257:612–614, 1975.

    Article  PubMed  CAS  Google Scholar 

  49. Xu JY, Gorny MK, Palker T, et al: Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol 65:4832–4838, 1991.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Zoltán ProhÁszka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

ProhÁszka, Z., TÓth, F.D., BÁnhegyi, D. et al. Role of complement and antibodies in the control and facilitation of HIV disease. Pathol. Oncol. Res. 3, 296–302 (1997). https://doi.org/10.1007/BF02904290

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02904290

Key words

Navigation